Eli Lilly, Weight Loss Pill

Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
 · 4dSTAT
How much weight loss is too much? Pharma is pushing the limit with new obesity drugs
In ongoing trials of Eli Lilly’s next-generation obesity drug, several participants are running into an issue they never expected: They are losing too much weight. One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound.
Eli Lilly aims to invest in ‘big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in obesity.
U.S. attorneys general forum urges FDA to act against counterfeit weight loss drugs
U.S. attorneys general urge the FDA to combat counterfeit versions of weight loss drugs developed by Eli Lilly (LLY) and Novo Nordisk (NVO). Read more here.
FiercePharma2d
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.
Lilly, Novo dominance to continue as TD Cowen lifts 2030 GLP-1 sales forecast by 38%
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes drugs by 38% to $139B. REad more here.
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.